Όλο το DSpace

Πλοήγηση ανά Θέμα "cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine"

Αποτελέσματα 1-4 από 4

    • Bing–Neel syndrome presenting with bilateral lumbar radiculopathy: A case report of a rare clinical entity [Síndrome de Bing-Neel que se presenta con radiculopatía lumbar bilateral: reporte de caso de una entidad clínica rara] 

      Brotis A.G., Palassopoulou M., Kapsalaki E.Z., Paschalis T., Papastergiou V., Fountas K.N. (2022)
      The differential diagnosis of bilateral lower extremity weakness is broad. We present a very rare case of a 48-year old male patient, with walking difficulties due to Bing–Neel syndrome. On clinical examination, there was ...

    • Identification of Very Low-Risk Subgroups of Patients with Primary Mediastinal Large B-Cell Lymphoma Treated with R-CHOP 

      Vassilakopoulos T.P., Michail M., Papageorgiou S., Kourti G., Angelopoulou M.K., Panitsas F., Sachanas S., Kalpadakis C., Katodritou E., Leonidopoulou T., Kotsianidis I., Hatzimichael E., Kotsopoulou M., Dimou M., Variamis E., Boutsis D., Terpos E., Dimopoulou M.N., Karakatsanis S., Michalis E., Karianakis G., Tsirkinidis P., Vadikolia C., Poziopoulos C., Pigaditou A., Vrakidou E., Economopoulos T., Kyriazopoulou L., Siakantaris M.P., Kyrtsonis M.-C., Symeonidis A., Anargyrou K., Papaioannou M., Hatjiharissi E., Vervessou E., Tsirogianni M., Palassopoulou M., Gainaru G., Stefanoudaki E., Zikos P., Tsirigotis P., Tsourouflis G., Assimakopoulou T., Konstantinidou P., A. Papadaki H., Megalakaki K., Dimopoulos M.-A., Pappa V., Karmiris T., Roussou P., Panayiotidis P., Konstantopoulos K., Pangalis G.A. (2021)
      Background: R-CHOP can cure approximately 75% of patients with primary mediastinal large B-cell lymphoma (PMLBCL), but prognostic factors have not been sufficiently evaluated yet. R-da- EPOCH is potentially more effective ...

    • Positron emission tomography after response to rituximab-CHOP in primary mediastinal large B-cell lymphoma: impact on outcomes and radiotherapy strategies 

      Vassilakopoulos T.P., Papageorgiou S.G., Angelopoulou M.K., Chatziioannou S., Prassopoulos V., Karakatsanis S., Arapaki M., Mellios Z., Sachanas S., Kalpadakis C., Katodritou E., Leonidopoulou T., Kotsianidis I., Hatzimichael E., Kotsopoulou M., Dimou M., Variamis E., Boutsis D., Terpos E., Michali E., Karianakis G., Tsirkinidis P., Vadikolia C., Poziopoulos C., Pigaditou A., Vrakidou E., Siakantaris M.P., Kyrtsonis M.-C., Symeonidis A., Anargyrou K., Papaioannou M., Chatziharissi E., Vervessou E., Tsirogianni M., Palassopoulou M., Gainaru G., Mainta C., Tsirigotis P., Assimakopoulou T., Konstantinidou P., Papadaki H., Dimopoulos M.-A., Pappa V., Karmiris T., Roussou P., Datseris I., Panayiotidis P., Konstantopoulos K., Pangalis G.A., Rondogianni P. (2021)
      End-of-treatment (EoT) PET/CT is used as a guide to omit radiotherapy (RT) patients with primary mediastinal large B-cell lymphoma (PMBCL). We present the mature and extended results of a retrospective study evaluating the ...

    • Real-life Experience With Rituximab-CHOP Every 21 or 14 Days in Primary Mediastinal Large B-cell Lymphoma 

      Karakatsanis S.J., Bouzani M., Symeonidis A., Angelopoulou M.K., Papageorgiou S.G., Michail M., Gainaru G., Kourti G., sachanas S., Kalpadakis C., Katodritou E., Leonidopoulou T., Kotsianidis I., Hatzimichael E., Kotsopoulou M., Dimou M., Variamis E., Boutsis D., Kanellias N., Dimopoulou M.N., Michali E., Karianakis G., Tsirkinidis P., Vadikolia C., Poziopoulos C., Pigaditou A., Vrakidou E., Economopoulos T., Kyriazopoulou L., Siakantaris M.P., Kyrtsonis M.-C., Anargyrou K., Papaioannou M., Hatjiharissi E., Vervessou E., Tsirogianni M., Palassopoulou M., Stefanoudaki E., Zikos P., Tsirigotis P., Tsourouflis G., Assimakopoulou T., Verrou E., Papadaki H., Lampropoulou P., Dimopoulos M.-A., Pappa V., Konstantopoulos K., Karmiris T., Roussou P., Panayiotidis P., Pangalis G.A., Vassilakopoulos T.P. (2022)
      Background/Aim: Primary mediastinal large Bcell lymphoma (PMLBCL) is an aggressive B-cell non- Hodgkin lymphoma (NHL), whose prognosis has greatly improved since the incorporation of the anti-CD20 monoclonal antibody ...